Illumina, Investors Launch Consumer Genetics Firm

With $100 million in initial funding, Helix aims to make personal genomics accessible.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Illumina Hiseq 2000 sequencers at BGIWIKIMEDIA, SCOTTED400Along with investment firms Warburg Pincus and Sutter Hill Ventures, Illumina is launching a consumer genetics company called Helix, The New York Times’s DealBook reported this week (August 18). Together, the three firms are committing $100 million to the Bay Area-based startup, which Tech Crunch compared to “an application program interface for personalized genetics on one hand and an iTunes for gene-based applications and services on the other.”

Illumina Chief Executive Jay Flatley will take the helm of this new company. According to Bloomberg Business, Helix has already partnered with the Mayo Clinic—which has invested in the startup—and LabCorp.

“The real question in our minds remains the pacing of market development as well as the potential challenges of an uncertain regulatory environment,” Evercore ISI analysts Ross Muken and Vijay Kumar wrote in a note following the Helix announcement, Bloomberg Business reported.

Flatley told MIT Technology Review that Helix aims to make personal genomics more accessible. “With Helix,” Tech Review reported, “companies won’t have to invest in starting a laboratory anymore. Instead, he says, any developer with a computer will be able to start a genomics company.”

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies